首页> 美国卫生研究院文献>Alzheimers Research Therapy >The C9ORF72 mutation brings more answers and more questions
【2h】

The C9ORF72 mutation brings more answers and more questions

机译:C9ORF72突变带来更多答案和更多问题

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The clinical, neuropsychiatric and neuroimaging features of patients who carry the important new C9ORF72 mutation are discussed in this special series of Alzheimer's Research & Therapy. First reported in November 2011, the C9ORF72 mutation is the most common mutation associated with both frontotemporal dementia and amyotrophic lateral sclerosis in the Western hemisphere and Europe. It is a gene with strong penetrance, and the vast majority of subjects with the C9ORF72 mutation die from a neurodegenerative condition. The most common clinical manifestation of disease in gene carriers is behavioral variant frontotemporal dementia. An extremely long hexanucleotide repeat (usually greater than 400), appears to lead to ribonucleic acid aggregates within the nucleus and suppression of gene expression. Finding therapies for C9ORF72 will be difficult and require novel therapeutic approaches that involve suppression of the expression of the C9ORF72 repeat.
机译:阿尔茨海默氏症研究与治疗这一特殊系列讨论了携带重要新C9ORF72突变的患者的临床,神经精神病学和神经影像学特征。 C9ORF72突变于2011年11月首次报道,是西半球和欧洲与额颞叶痴呆和肌萎缩性侧索硬化症相关的最常见突变。它是一种具有强渗透性的基因,绝大多数具有C9ORF72突变的受试者都死于神经退行性疾病。基因携带者中最常见的疾病临床表现是行为变异额颞痴呆。极长的六核苷酸重复序列(通常大于400)似乎会导致核内的核糖核酸聚集并抑制基因表达。寻找C9ORF72的疗法将是困难的,并且需要涉及抑制C9ORF72重复序列表达的新颖治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号